Loading...
In an occasional column, Journal Watch Psychiatry editors briefly comment on review articles. These annotations were written by Barbara Geller, MD, Peter Roy-Byrne, MD, and Joel Yager, MD.
Immunosuppression and schizophrenia. These authors argue for a trial of immunosuppressive therapy for patients with schizophrenia, reasoning that many familial aspects, the course of disease, and some biological markers in schizophrenia are similar to those in many established autoimmune diseases.1 Their rationales include that schizophrenia patients, compared with healthy populations, have a high prevalence of some autoimmune diseases and that a very early trial of low-dose steroid therapy was successful (albeit replications at higher doses were not). Eve…